GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » GE HealthCare Technologies Inc (FRA:L0T) » Definitions » Debt-to-EBITDA

GE HealthCare Technologies (FRA:L0T) Debt-to-EBITDA : 2.88 (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is GE HealthCare Technologies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

GE HealthCare Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €1,010 Mil. GE HealthCare Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €8,660 Mil. GE HealthCare Technologies's annualized EBITDA for the quarter that ended in Sep. 2024 was €3,355 Mil. GE HealthCare Technologies's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was 2.88.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for GE HealthCare Technologies's Debt-to-EBITDA or its related term are showing as below:

FRA:L0T' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.12   Med: 1.41   Max: 3.09
Current: 3.09

During the past 5 years, the highest Debt-to-EBITDA Ratio of GE HealthCare Technologies was 3.09. The lowest was 0.12. And the median was 1.41.

FRA:L0T's Debt-to-EBITDA is ranked worse than
57.81% of 448 companies
in the Healthcare Providers & Services industry
Industry Median: 2.465 vs FRA:L0T: 3.09

GE HealthCare Technologies Debt-to-EBITDA Historical Data

The historical data trend for GE HealthCare Technologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GE HealthCare Technologies Debt-to-EBITDA Chart

GE HealthCare Technologies Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
- 0.14 0.12 2.67 2.81

GE HealthCare Technologies Quarterly Data
Dec19 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.77 2.79 3.03 2.82 2.88

Competitive Comparison of GE HealthCare Technologies's Debt-to-EBITDA

For the Health Information Services subindustry, GE HealthCare Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GE HealthCare Technologies's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, GE HealthCare Technologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where GE HealthCare Technologies's Debt-to-EBITDA falls into.



GE HealthCare Technologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

GE HealthCare Technologies's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1023.372 + 8020.999) / 3221.421
=2.81

GE HealthCare Technologies's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1010.021 + 8660.412) / 3355.324
=2.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


GE HealthCare Technologies  (FRA:L0T) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


GE HealthCare Technologies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of GE HealthCare Technologies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


GE HealthCare Technologies Business Description

Traded in Other Exchanges
Address
500 West Monroe Street, Chicago, IL, USA, 60661
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (54% of revenue), ultrasound (18%), patient care solutions (16%), and pharmaceutical diagnostics (12%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 44%, 26%, 14%, and 16% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (33% of revenue), pharmaceutical diagnostics (12%), and digital solutions (6%).

GE HealthCare Technologies Headlines

No Headlines